- Trial phase
- Unknown, no clinical trials or regulatory filings found for ARGX-213.
- Time to market
- Unknown, ARGX-213 has no publicly disclosed development status.
- Why 1/10
- No hard, dated catalyst exists for ARGX-213 because the drug is not found in any accessible clinical-trial registry, FDA database, or company disclosure. Without a known development stage or upcoming readout, the impact score defaults to the lowest tier.
ARGX-213 does not appear in any accessible clinical-trial registry, FDA database, press release, or pipeline disclosure for argenx. Investors should verify the drug name, it may be a preclinical internal code, a typo, or a candidate that was discontinued before public disclosure. Argenx's publicly disclosed pipeline (efgartigimod/VYVGART, empasiprubart/ARGX-117, ARGX-119, FB102) contains no ARGX-213.
Price Chart
Executive Summary
ARGX-213 is not found in any accessible clinical-trial registry, FDA database, SEC filing, press release, or pipeline disclosure for argenx SE (Nasdaq: ARGX). The drug name does not appear among argenx's known pipeline candidates, efgartigimod (VYVGART), empasiprubart (ARGX-117), ARGX-119, or the recently acquired FB102. ARGX-213 may be a very early preclinical internal code, a discontinued candidate, or a name error. Argenx itself is a well-capitalized immunology leader with a $5.2B cash position, strong analyst support (23 of 26 analysts rate Buy/Strong Buy, mean price target ~$1,149), and a growing approved-drug franchise in VYVGART. However, with no verifiable information on ARGX-213 specifically, no informed investment thesis can be built around this drug.
How It Works
Unknown. ARGX-213 is not described in any accessible public source. Argenx's known pipeline focuses on monoclonal antibodies targeting the FcRn receptor (efgartigimod), complement pathway (empasiprubart/ARGX-117), and CD122 (FB102). ARGX-213 may be an early preclinical candidate in a similar immunology/autoimmune disease area, but its mechanism has not been publicly disclosed.
Trial Status
No clinical trials, FDA actions, or pipeline disclosures referencing ARGX-213 were found in any accessible database. The drug may be a preclinical internal code that was never publicly disclosed or advanced.
The Two-Sided Case
Upcoming Catalysts
- None identified for ARGX-213 specifically. For argenx broadly: Phase 3 ALKIVIA myositis data readout, sBLA submission for IMNM, and MMN Phase 3 data in 2H 2026.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ARGENX SE 6-K ARGX ·Originating report